Our Terms of Service and Privacy Policy have changed.
By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.
By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.
| 289.46 Delayed Data As of Sep 30 |  +3.59 / +1.26%Today’s Change | 240.03 Today|||52-Week Range 343.87 | -14.44% Year-to-Date |
The investment seeks to track the investment results of the NASDAQ Biotechnology Index, which contains securities of NASDAQ ® listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals and that also meet other eligibility criteria determined by Nasdaq, Inc. The fund generally invests at least 90% of its assets in securities of the index and in depositary receipts representing securities of the index. It may invest the remainder of its assets in certain futures, options and swap contracts, cash and cash equivalents. It is non-diversified.
| Buy These 4 Stocks and Beat Biotech's Slump Sep 30 / TheStreet.com - Paid Partner Content | The Zacks Analyst Blog Highlights: iShares Gold ETF, VanEck Vectors Coal ETF, Raytheo... Sep 26 / Zacks.com - Paid Partner Content |
| Clinton Apparently Won First Debate: ETFs in Focus Sep 27 / Zacks.com - Paid Partner Content | Prepare for a Trump Presidency With These Stocks & ETFs Sep 23 / Zacks.com - Paid Partner Content |
| Biotech ETFs May Be a Prescription for Investment Success, Especially If Trump Become... Sep 26 / TheStreet.com - Paid Partner Content | ETFs in Focus on the Nasdaq Rally Sep 23 / Zacks.com - Paid Partner Content |
| 1 month | +3.03% | 3 years | +11.48% | |
| 3 months | +12.41% | 5 years | +25.62% | |
| 1 year | -4.29% | Since inception | +7.17% |
| Previous close | $285.87 |
| Open day’s range | 283.72 – 290.53 |
| Net asset value (NAV) | 289.35 (09/30/2016) |
| Daily volume | 2,138,141 |
| Average volume (3 months) | 1,535,816 |
| IBB | Category | |
|---|---|---|
| Performance 5-yr return | +25.62% | +15.32% |
| Expense Gross exp ratio | 0.47% | 0.48% |
| Risk 5 year sharpe ratio | 1.10 | 1.16 |
| Net assets | $7.3B | $1.1B |
| Average market cap | $16.0B | $37.2B |
| Average P/E | 20.1 | 20.2 |
| Dividend / Share | -- | 0.22% |
| XLV Health Care Select Sector SPDR® Fund |
| RYH Guggenheim S&P 500® Equal Weight Health... |
| VHT Vanguard Health Care Index Fund ETF Shar... |
| Healthcare | 99.91% |
| Business service | 0.09% |
| Consumer goods | 0.00% |
| Consumer service | 0.00% |
| Energy | 0.00% |
| AMGN Amgen | 8.49% |
| BIIB Biogen | 8.32% |
| CELG Celgene | 7.97% |
| GILD Gilead Sciences | 7.10% |
| REGN Regeneron Pharmaceuticals | 7.01% |
| ILMN Illumina Inc | 4.46% |
| VRTX Vertex Pharmaceuticals Inc | 4.00% |
| MYL Mylan NV | 3.85% |
| ALXN Alexion Pharmaceuticals Inc | 3.29% |
| SHPG Shire | 2.98% |
